Callio Therapeutics is developing novel dual-payload antibody-drug conjugates (ADCs) designed to address resistance to existing cancer therapies, ...

Preliminary clinical results of the MYTHIC study will be presented, revealing for the first time data of the combination of WEE1 and PKMYT1 inhibition (zedoresertib and lunresertib) for the treatment ...

Antibody-drug conjugates (ADCs) have been in development for decades, but only about a dozen have received FDA approval. Clearly, ADCs still have some major challenges. Yet they have done little to ...

The e-posters will be available for browsing at the AACR virtual meeting platform beginning at 12:00 PM PT on April 17, as well as on the OBI Pharma website ( beginning on April 18. 1 AACR Annual ...

Add Yahoo as a preferred source to see more of our stories on Google. Innovation in linkers Antibody-drug conjugate (ADC) developers say innovations to linkers, the proteins bridging antibodies to ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug discovery, today announced the formation of its Scientific Advisory Board (SAB), ...

Clinical-stage PTK7 ADC KIVU-107 shows strong preclinical anti-tumor activity, favorable pharmacokinetics and improved ...

ADC innovation is accelerating beyond traditional cytotoxins into dual-payload constructs, high-DAR species, degrader-antibody conjugates, and next-generation modalities. However, this rapid evolution ...

From payload optimization to integrated GMP manufacturing, companies aim to elevate oncology ADCs to standard of care.

DUBLIN--(BUSINESS WIRE)--The "Antibody-drug Conjugates: Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. Antibody-drug conjugates (ADCs) are therapies that ...